Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies

BackgroundCD19 combined with CD22 or CD20 therapy is a promising immunotherapy approach for the treatment of hematological malignancies. Dual-targeted CD19/CD22 CAR T and CD19/CD22 CAR T-cell therapy are currently being evaluated in clinical trials, and the extent of improvement using CD19 in combin...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoshuang Yuan, Feiqing Wang, Peng Zhao, Bo Yang, Xu Yang, Ting Tian, Bingbing Li, Guangyang Liu, Sanbin Wang, Dongxin Tang, Zhixu He, Yanju Li, Yang Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
car-t
hematological malignancies
chimeric antigen receptor
immunotherapy
cancer therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1577360/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1577360/full

Similar Items